Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Magdalena Balp

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Journal of Clinical Medicine|February 26, 2025
Prevalence and Burden of Chronic Spontaneous Urticaria in Japan: A Cross-Sectional StudyMichihiro Hide, Akihito Uda, Fuyuko Maki, et al.
Allergy and Asthma Proceedings|February 21, 2018
Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United StatesJacqueline Eghrari-Sabet, Ellen Sher, Abhishek Kavati, et al.
Dermatology and Therapy|February 12, 2018
Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United StatesPaul V Williams, Abhishek Kavati, Dominic Pilon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 6, 2025
Prevalence, treatment and burden of chronic spontaneous urticaria in five European countriesMaria-Magdalena Balp, Kathryn Krupsky, Shaloo Gupta, et al.
The Patient|December 18, 2020
Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative StudyLynda C Doward, Maria-Magdalena Balp, James Twiss, et al.
Ejhaem|February 20, 2026
Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 InhibitorsShreyans Gandhi, Markus P Radsak, Yasutaka Ueda, et al.
Clinical and Translational Allergy|February 26, 2022
Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticariaAna Giménez-Arnau, Marcus Maurer, Jonathan Bernstein, et al.
Clinical and Translational Allergy|August 20, 2016
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studiesAna M Gimenéz-Arnau, Sheldon Spector, Evgeniya Antonova, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes studyMaria-Magdalena Balp, Nancy Krieger, Raymond Przybysz, et al.
Pharmacoeconomics|May 23, 2016
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous UrticariaJonathan Graham, Doreen McBride, Donald Stull, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Journal of Clinical Medicine|February 26, 2025
Prevalence and Burden of Chronic Spontaneous Urticaria in Japan: A Cross-Sectional StudyMichihiro Hide, Akihito Uda, Fuyuko Maki, et al.
Allergy and Asthma Proceedings|February 21, 2018
Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United StatesJacqueline Eghrari-Sabet, Ellen Sher, Abhishek Kavati, et al.
Dermatology and Therapy|February 12, 2018
Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United StatesPaul V Williams, Abhishek Kavati, Dominic Pilon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 6, 2025
Prevalence, treatment and burden of chronic spontaneous urticaria in five European countriesMaria-Magdalena Balp, Kathryn Krupsky, Shaloo Gupta, et al.
The Patient|December 18, 2020
Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative StudyLynda C Doward, Maria-Magdalena Balp, James Twiss, et al.
Ejhaem|February 20, 2026
Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 InhibitorsShreyans Gandhi, Markus P Radsak, Yasutaka Ueda, et al.
Clinical and Translational Allergy|February 26, 2022
Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticariaAna Giménez-Arnau, Marcus Maurer, Jonathan Bernstein, et al.
Clinical and Translational Allergy|August 20, 2016
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studiesAna M Gimenéz-Arnau, Sheldon Spector, Evgeniya Antonova, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes studyMaria-Magdalena Balp, Nancy Krieger, Raymond Przybysz, et al.
Pharmacoeconomics|May 23, 2016
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous UrticariaJonathan Graham, Doreen McBride, Donald Stull, et al.
Pageof 6